Background: Transcatheter aortic valve replacement (TAVR) is typically performed under general
avalvular leaks (PVL) and permanent pacemaker implantation (PPM).
However, the GA approach is also associated with prolonged mechanical ventilation (which in turn increases the risk of ventilator-associated pneumonia), prolonged hospital and intensive care unit (ICU) length of stay (LOS), and the need for inotropic and/or vasopressor support [3] .
Additionally, there is growing evidence that TAVR can be safely performed under LA without the need for endotracheal intubation and mechanical ventilation [4] . While, several studies have compared LA and GA in patients undergoing TAVR, the choice of anesthesia (LA vs. GA) remains ambiguous and is often dependent on institutional and practitioner preferences [5] . Therefore, we performed a systematic literature review and comprehensive meta-analysis to study the comparative outcomes of LA and GA for patients with severe aortic stenosis undergoing TAVR.
| M A TE RI A L S A ND M E TH ODS
We developed a protocol for the systematic review, which we posted online and registered in PROSPERO (CRD42016047170), and followed reporting recommendations from Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [6] .
| Data sources and searches
We conducted a computerized search of PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and Google Scholar databases. This search was last assessed as up-to-date on March 1, 2017. We also conducted a manual search of references of each study included in our analysis.
| Study selection
We included randomized and nonrandomized studies that (1) directly compared outcomes of LA and GA among patients undergoing TAVR (all types of approaches); and (2) reported at least 1 of the end points.
We excluded studies that (1) included patients younger than 18 years; (2) reported outcomes with only LA or only GA; and (3) lacked data detailing at least 1 of the outcomes included in our analysis. We used the following search terms without language restrictions: anesthesia, anesthetic, aortic valve, aortic valve implantation, aortic valve replacement, aortic valve stenosis, conscious sedation, GA, LA, percutaneous, sedation, TAVR, transcatheter valve implantation, transcatheter. Conference abstracts were excluded from our analysis. Studies evaluating monitored anesthesia care or light sedation were included as LA for the purpose of this meta-analysis.
| Data extraction and quality assessment
Data for clinical outcomes and study characteristics of patients in each study were abstracted independently by 2 reviewers (P.A.V. and K.N.) using a standardized data extraction form. Disagreements were resolved by a third reviewer (D.F.B.). Two reviewers (P.A.V. and D.M.)
independently assessed the risk of bias of randomized controlled trials by using standard criteria defined in the Cochrane Handbook for Systematic Reviews of Interventions [4] and the Newcastle-Ottawa Scale for nonrandomized studies [7] .
| Study outcomes
The primary end point was 30-day all-cause mortality. The secondary end points included stroke, cardiovascular mortality, myocardial infarction (MI), PPM, acute kidney injury (AKI), vascular complications, major bleeding, use of inotropic/vasopressor drugs, conduction abnormalities other than complete heart block, annular rupture, moderate to severe PVL, procedural success defined as successful device deployment, hospital LOS, intensive care unit LOS, procedure time, and fluoroscopy time.
The outcomes of interest were evaluated at the longest available follow-up for quantitative and qualitative appraisal. The Valve VILLABLANCA ET AL.
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Academic Research Consortium-2 end point definitions were used as a guideline to assess short-term outcomes when applicable [8] .
| Data synthesis and analysis
Data were summarized across treatment arms using the MantelHaenszel risk ratio (RR) for dichotomous data and the difference of the mean (DM) for continuous data with fixed-effect models. We evaluated heterogeneity of effects by using the Higgins I 2 and Q-statistic test. In cases of heterogeneity (defined as I 2 > 25%), random-effects models were used. Statistical significance was set at a P value < 0.05 (2-tailed).
To address publication bias, we used 4 methods: funnel plots, the Begg-Mazumdar test, the Egger test, and the Duval and Tweedie test.
Using event rates as dependent variables, meta-regression analyses were performed to determine whether the 30-day mortality effect of LA was modulated by prespecified factors (age, female sex, cerebrovascular disease, coronary artery disease, chronic kidney disease, diabetes mellitus, hypertension, chronic obstructive pulmonary disease, ejection fraction, pulmonary hypertension, peripheral vascular disease, and New
York Heart Association class II-IV), which would enable identification of sources of heterogeneity between studies. All variables were represented as a proportion in the studies. Meta-regression was performed with an unrestricted maximum-likelihood method (inverse varianceweighted regression) on the event rate, which was log-transformed before being used as an independent variable in the linear metaregression analyses. Finally, chronologic cumulative analyses by publication year were used to test if the effect size and precision shifts were based on technical advancement of TAVR technology and an acquired learning curve. The statistical analyses were performed by using the Comprehensive Meta-Analysis software, version 2.0 (Biostat).
The first and second author (PAV and DM) performed all analyses independently. Both authors have a Masters degree in clinical research and biostatistics. We used an intention-to-treat analysis, so that if patients converted during the procedure from one approach to the other (LA to GA), they were considered to be in their originally assigned group.
| R ESU L TS
The initial search strategy identified 1,717 potential articles ( Figure 1 ).
After removing duplicates and articles not meeting inclusion criteria, we screened 213 titles. Finally, 26 studies satisfied the inclusion criteria, all of which were published in English [3, . All studies were observational except for one randomized controlled trial [28] . The overall cohort from the studies comprised 10,572 patients. Tables 1   and 2 include further details of the studies' baseline characteristics.
Although study quality was rated high overall, the studies shared a risk of performance bias because participants could not be blinded to the intervention. Tables 1 and 2 in the Supporting Information summarize quality appraisals of the included studies. 
Cardiovascular mortality
There were 68 deaths reported due to cardiovascular disease: 30 of 1,050 (2.9%) patients in the LA group and 38 of 953 (4.0%) patients in the GA group. These differences were not significant (RR, 0.73; 95% CI, 0.46-1.15; P 5.18) (Supporting Information, Figure 1A ). Figure 3A ).
Myocardial infarction

Permanent pacemaker
A total of 476 PPM were reported: 326 in 2,646 patients (12.3%) in the LA group compared with 150 in 1,619 patients (9.3%) in the GA group. The difference was not significant (RR, 1.05; 95% CI, 0.87-1.26; Figure 1B ).
Acute kidney injury
A total of 504 AKI were reported: 293 in 4,515 patients (6.5%) in the LA group compared with 211 of 4,464 patients (4.7%) in the GA group.
The difference was not significant (RR, 0.94; 95% CI, 0.68-1.30; Figure 3B ). 
Vascular complications
A total of 551 vascular complications were reported: 278 in 3,602 patients (7.7%) in the LA group compared with 273 in 4,297 patients (6.4%) in the GA group. This difference was not significant (RR, 0.92; 95% CI, 0.70-1.21; P 5 0.56) ( Figure 4A ).
Major bleeding
A total of 469 major bleeding events were reported: 261 in 4,281 patients (6.1%) in the LA group compared with 208 in 4,390 patients (4.7%) in the GA group. The difference was not significant (RR, 0.92; 95% CI, 0.64-1.31; P 5 0.63) ( Figure 4B ).
Inotropic or vasopressor drugs
Use of inotropic or vasopressor drugs was reported for 273 patients:
107 of 1,837 patients (5.8%) in the LA group compared with 166 of 2,260 patients (7.3%) in the GA group. This reduction in the use of inotropic/vasopressor drugs was significant, favoring LA over GA (RR, 0.45; 95% CI, 0.28-0.72; P < 0.001) (Supporting Information, Figure   1C ). Figure 1D ).
Conduction abnormalities
Annular rupture
Annular rupture events were reported for 12 patients: 6 of 1,024
(0.6%) in the LA group compared with 6 of 1,501 (0.4%) in the GA group. The difference was not significant (RR, 1.13; 95% CI, 0.20-6.31; P 5 0.89) (Supporting Information, Figure 1E ).
Paravalvular leak
A total of 547 PVL were reported: 237 in 2,659 patients (8.9%) in the LA group compared with 310 in 3,867 patients (8%) in the GA group.
The difference was not significant (RR, 1.01; 95% CI, 0.78-1.30; Figure 1F ).
Procedural success
The procedure was successful in 95.4% of the LA group and 98.2% of the GA group. The conversion rate from LA to GA was 7.9%. There was no significant difference in procedural success favoring LA over GA (RR, 1.40; 95% CI, 0.67-2.96; P 5 0.37) (Supporting Information, Figure 1G ).
Hospital length of stay
The mean hospital LOS was 7.2 days in the LA group and 9.3 days in the GA group. There was a significant difference favoring LA over GA (DM, 22.09; 95% CI, 23.02 to 21.16; P < 0.001) ( Figure 5A ).
Intensive care unit length of stay
The average intensive care unit LOS was 1.3 days in the LA group and 1.5 days in the GA group, with a significantly shorter ICU LOS favoring the LA group (DM, 20.18; 95% CI, 20.31 to 20.04; P 5 0.01) ( Figure 5B ). 
Procedure time
The average procedure time was 97 min in the LA group and 124 min in the GA group. There was a significant difference favoring LA over GA (DM, 225.02; 95% CI 232.70 to 217.35; P < 0.001) (Supporting Information, Figure 1H ).
Fluoroscopy time
The average fluoroscopy time was 101 min in the LA group and 120 min in the GA group. There was a significant difference favoring LA over GA (DM, 21.63; 95% CI, 23.02 to 20.24; P 5 0.02) (Supporting Information, Figure 1I ).
| Meta-regression
Meta-regression analysis showed no significant interaction between mortality and patient characteristics among patients undergoing TAVR with LA (Supporting Information, Figure 2A -L).
| Sensitivity analyses
In the sensitivity analyses, with each study removed individually, the only significant outcome that changed in the summary risk ratio 
| Cumulative analysis
Only mortality, use of inotropic/vasopressor drugs, and hospital LOS were changed significantly (P < 0.05) in the overall final effect in the chronologic cumulative analysis for each outcome before inclusion of all studies in the final effect summary (Supporting Information, Figure 5A -Q).
| Bias
Funnel plots did not show asymmetry suggesting bias except for AKI, MI, and fluoroscopy time (Supporting Information, Figure 6A -Q). 
| D I SCUSSION
In our large meta-analysis of 26 studies with over 10,000 patients, we
show that patients undergoing TAVR with LA have lower 30-day mortality, shorter procedure time, fluoroscopy time, ICU length of stay, hospital length of stay, and reduced need for inotropic support. The risk of peri-procedural adverse events such as PPM, residual PVL, annular rupture, MI, stroke, and vascular complications was comparable in both groups. These results were consistent on multiple sensitivity analyses. These analyses also allowed us to consider the possibility of data bias from recent articles that could reflect important new advancements in the field.
Our results are different in several key outcomes as compared with previously published systematic reviews and meta-analyses [4, 5, 34] . Three previous meta-analyses reported similar all-cause mortality between patients undergoing TAVR with LA or GA [4, 5, 34] . In the most recent analysis of 10 studies by Maas et al. [5] , the relative risk (CI) for mortality (0.91 [0.53-1.56]) favored LA. However, the confidence intervals were large, and we postulate that this effect may have been significant had the sample size been larger [5] . Mortality after TAVR is dictated in the first 48 hr by cardiac causes and in the interval between 48 hr and 30 days by predominantly noncardiac causes, such as stroke and sepsis [35] . In our analyses, the incidence of stroke and cardiovascular mortality was similar between the 2 groups; therefore, we presume that non-cardiac causes of death, such as lifethreatening infections, may have driven the increased mortality seen in patients undergoing TAVR with GA. In the GA group, infections can be attributed to use of tracheal intubation, mechanical ventilation, hemodynamic instability, and prolonged hospital and ICU stays [14] . A large meta-analysis of over 21 million anesthetic procedures worldwide reported that despite a decrease in deaths from anesthesia over the years; from the 1990s to 2011, GA was either solely responsible for or contributed to 177 postoperative deaths and 719 cardiac arrests per million surgical patients. Of note, this number was even greater for higher-risk patients, such as those undergoing TAVR [36] . While it is possible that our outcomes may be have been influenced by selection bias, wherein patients with worse comorbidity profiles underwent TAVR under GA (as most centers have greater experience with this technique), our extensive meta-regression analysis failed to reveal any association of age, gender or comorbidities on the overall effect. Additionally, data from the STS/TVT registry, which was presented at the SCAI 2016 scientific sessions, revealed that patients undergoing TAVR with LA had a lower 30-day mortality (2.96% vs. 4.01%, P < 0.001).
These results were obtained after propensity matching the groups for 51 baseline variables included valve type and carotid stenosis [37] .
Chronological cumulative analysis revealed that 30-day mortality in the LA group, while initially comparable to GA, became significantly lower than GA through addition of studies over time. This may be indirect evidence of a learning curve associated with use of LA.
We also report a longer procedure time for patients undergoing TAVR with GA, which may be attributed to the time required for surgical dissection of the femoral arteries in selected patients, preoperative intubation, weaning from intubation, extubation, and recovery from GA. Importantly, the less common TAVR approaches, such as the transapical and transaortic approach, require GA in contrast to the most commonly used transfemoral approach, which has the option of LA [38] . The shorter procedure time for LA would presumably allow for decreased health care resource utilization and increased availability of the cardiac catheterization laboratory for other procedures. In addition, more hemodynamic stability (as evidenced by decreased need for vasopressor medications in patients undergoing TAVR with LA) may reduce ICU admission and allow for shorter hospitalizations (as seen in our analysis). These factors would likely make LA a cost-effective alternative. This is especially important given that the incremental costeffectiveness ratio for TAVR remains on average above $800,000 per quality-adjusted life-year (converted from current European data [e750,000]) [39] . Motloch et al. [3] reported that patients undergoing TAVR with LA incur only 63.4% of the costs that patients who have GA incur. However, an anesthesiologist or a nurse anesthetist was not involved in patient care in their LA group, which could have led to the lower costs.
Although reducing costs is essential, we believe it prudent and essential to have a multidisciplinary team that includes a cardiac anesthesiologist involved in the care of patients undergoing TAVR, as recommended by Centers for Medicare & Medicaid Services [40] . This is especially important given the concern that LA might fail and that conversion to GA might be needed, which has been reported to occur at a rate as high as 17% [11] . However, most conversions in TAVR patients are due to non-emergent vascular complications unrelated to anesthesia [11, 14] . Chronic obstructive pulmonary disease, advanced age, and preprocedure hemodynamic instability are associated with hemodynamic instability after emergent intubation. As all 3 of these risk factors are frequently present in the cohort of patients undergoing TAVR, involvement of a cardiac anesthesiologist becomes even more important in the event of LA failure [41, 42] .
GA offers several important advantages over LA, including reliable patient immobility and ease of use of intraprocedural TEE, which may be helpful for early detection of dissection, tamponade, and valve embolization. However, our analysis reveals that this benefit does not translate into reduced 30-day mortality or decreased peri-procedural adverse events.
In their meta-analysis, Maas et al. and vasopressor. This may be a result of preexisting hypovolemia, blood loss, and the vasodilatory effect of anesthetic agents in patients undergoing TAVR with GA.
Our meta-analysis has a number of limitations. First, we used studylevel data that could be subject to selection bias that we could not easily determine. Second, the studies were methodologically heterogeneous.
However, we made every effort to present the outcomes as stratified analyses before the pooled estimate. Third, all studies in our analysis were observational except one, so randomization by anesthesia strategy was not done. In observational studies, potential biases are likely to be greater; therefore, the results should always be interpreted with caution when they are included in reviews and meta-analyses. Fourth, there was no standardization of study design, treatment exposure, protocols, and definitions of end points across studies. Fifth, the definitions and reporting of adverse outcomes and risk of enrolled patients differed across studies. Sixth, of those studies that reported LA and GA experience from a single center, the GA experience was consistently earlier in the institutional learning curve for TAVR, which could introduce bias and subject the results to confounding. The assignment to GA over LA was often based on patients' comorbidities, such as frailty or need for immobilization, and patients selected for LA may have been chosen because they were thought to pose less risk for technical complications or to need additional imaging. Seventh, barring 2 studies [20, 31] , all other studies included in our analysis had >90% patients undergoing TAVR through the transfemoral approach. Additional sensitivity analysis including studies with 100% transfemoral patients, showed consistency of our results in this population. Therefore, our results are primarily applicable to patients undergoing TAVR through a transfemoral approach and may not be applicable to other approaches. Eighth, crossover treatment was not reported consistently. This may have had a significant, unrecognized impact on the overall outcomes. Also, in some studies, there was a considerable loss to follow-up, but only a few studies provided detailed outcomes. Therefore, the effect of treatment duration on the observed risks and benefits in these studies was not well established.
These limitations were addressed by using sensitivity, cumulative analyses, and meta-regression analyses to overcome heterogeneity in the studies. We believe that the consistent magnitude and direction of the overall effect, including the stable results after the sensitivity analyses, support the validity of our results and justify the conclusions. We also believe that the data we have presented contribute substantially to addressing the increasingly relevant issue of LA versus GA for patients undergoing TAVR.
| C ONC LUSI ON S
Patients undergoing TAVR with LA have decreased 30-day mortality and have comparable risk for post-procedural adverse events. TAVR with LA is associated with shorter procedure times, ICU LOS, and hospital LOS. This meta-analysis provides preliminary evidence to suggest that LA can be considered as a potential alternative to GA for appropriate TAVR patients. However, a large randomized controlled trial is needed to allow for reliable validation of LA for TAVR, to identify those patients who may truly benefit from this approach and to define the circumstances under which LA should be considered.
